TY - JOUR T1 - Differences in prevalence of metabolic syndrome (MS) between male and female patients with moderate and severe obstructive sleep apnea. The definition is certainly an important factor JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P2295 AU - Maria Xanthoudaki AU - Paschalis Steiropoulos AU - Evangelia Nena AU - Maria Antoniadou AU - Maria Manidou AU - Stavros Anevlavis AU - Marios Froudarakis AU - Georgios Kolios AU - Demosthenes Bouros Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P2295.abstract N2 - Background: Obstructive Sleep Apnea (OSA) has been associated with Metabolic Syndrome (MS). Aim of the study was to evaluate the prevalence of MS in OSA patients using the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) and International Diabetes Federation (IDF) definition of the MS.Methods: Newly diagnosed, moderate-to-severe, consecutive OSA patients were included. Anthropometric characteristics and cardiovascular risk factors were recorded. Both ATP III and IDF criteria were used for diagnosing MS.Results: A total of 410 patients (323 male) were included to the study. Mean age was 54.9±12.5 years, mean Body Mass Index (BMI) was 35.74±6.88 kg/m2 and mean AHI was 50.5±24.7/hour. Using the IDF criteria, 41.5% of the patients (n=170) were diagnosed with MS, while using the ATP III definition, 157 patients (38.3%) met the criteria for MS.In moderate (AHI 15-29.9/h) OSA subgroup (n=106), a significant difference was found in MS prevalence between men and women using either ATP III (50% of women vs. 24.3% of men; p=0.021) or IDF criteria (63.3% of women vs. 28% of men, p=0.001). In severe (AHI ≥30/h) OSA subgroup (n=304), prevalence of MS was higher in women when the ATP III definition was used (52.6% of women vs. 37.4% of men, p=0.037) but not when the IDF definition was used (54.4% of women vs. 39.8% of men; p=0.053).Conclusion: Among patients with moderate-to-severe OSA, MS is highly prevalent and women are at higher cardiovascular risk. However, the estimated prevalence of MS can be significantly affected when different criteria of MS (ATP III or IDF) are used. ER -